We are experiencing one today by way of new classes of drugs known as GLP-1 receptor agonists. The development of these classes of drugs has been in the works for about two decades, but the world ...

Medical societies have updated guidelines allowing patients to continue using GLP-1 diabetes drugs before surgery, as new research indicates no increased risk of complications. The study also ...

Nov 1 (Reuters) - In a practice-changing guideline reversal, medical societies advised, opens new tab on Tuesday that most patients do not need to stop taking GLP-1 diabetes and weight-loss drugs ...

Wegovy is now a household name. If not for Novo Nordisk’s Lotte Bjerre Knudsen, the GLP-1 drugs it represents might have been a footnote in drug development history. Evidence started ...

an engineered peptide that binds to the GLP-1 receptor to spark metabolic effects. Semaglutide was initially approved for treating type 2 diabetes, where the drug is marketed as Ozempic.

Originally intended as a treatment for diabetes, GLP-1 drugs like Ozempic could be set to turn the food and drink industry upside down. Use of drugs containing glucagon-like peptide 1 (GLP-1), such as ...

Demand for weight loss drugs targeting GLP-1 has exploded in recent years, leading to disruptions in supply chains. Here are the companies racing for approval of their own versions of these highly ...

Eli Lilly has seen tremendous growth from its new GLP-1 drugs, which people have been using for weight loss. Sales growth should continue as the company increases production and looks to win ...

The new menu includes five smoothies “created to assist the millions of Americans currently taking prescription GLP-1 medications" Sabrina Weiss is the Editorial Assistant of PEOPLE's food ...

News and talk of GLP-1 drugs are everywhere these days—from their smash success in treating Type 2 diabetes and obesity to their astronomical pricing, drug shortages, compounding disputes ...

Researchers from Mass General Brigham and collaborators found that use of GLP-1 drugs to treat obesity more than doubled from 2022 to 2023 while rates of surgery dropped by one quarter. Key ...